3204–4464 Markham Street
Victoria, BC V8Z 7X8
Canada
250-483-0308
https://www.ipatherapeutics.com
版塊: Healthcare
行業: Biotechnology
全職員工: 102
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Jennifer Lynne Bath Ph.D. | CEO, President & Non-Independent Director | 1.01M | 無 | 無 |
Dr. Ilse Roodink | Chief Scientific Officer & Interim General Manager of IPA Europe, Oss | 274.49k | 無 | 無 |
Ms. Kristin Taylor CPA, M.B.A. | Chief Financial Officer | 無 | 無 | 無 |
Mr. David E. Orton | Chief Operating Officer | 無 | 無 | 無 |
Dr. Roland Romijn | Head of General Operations of the Utrecht site of IPA (Europe) | 無 | 無 | 無 |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.
截至 無 止,ImmunoPrecise Antibodies Ltd. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。